HBOT for Chronic Pain & Inflammation: What the Research Shows (2026)

1. Why Chronic Pain Is Different From Acute Pain

Chronic pain is not just acute pain that hasn't gone away. It represents a fundamental shift in how the nervous system processes signals — and at the center of that shift is systemic inflammation.

In healthy tissue, the inflammatory response is a time-limited repair mechanism. Pro-inflammatory cytokines like TNF-α (tumor necrosis factor-alpha) and IL-6 (interleukin-6) recruit immune cells, break down damaged tissue, and initiate healing. Then anti-inflammatory pathways take over and shut the process down.

In chronic pain conditions — fibromyalgia, rheumatoid arthritis, CRPS, and others — this shutdown fails. TNF-α and IL-6 remain chronically elevated. The resulting neuroinflammation sensitizes pain receptors, amplifies pain signals, and creates a self-reinforcing cycle where inflammation causes pain and pain perpetuates inflammation.

This is why conventional pain management often falls short. Opioids modulate the pain signal but don't address the underlying inflammatory driver. Anti-inflammatory medications reduce symptoms but rarely resolve the chronic state. And for many patients, the side effect burden of long-term pharmacological management is itself a significant problem.

HBOT works differently. It doesn't block a single receptor or cytokine — it changes the metabolic environment that sustains inflammation in the first place.

2. How HBOT Reduces Systemic Inflammation

To understand why HBOT works for pain, you need to understand oxygen's role in the inflammatory cascade — and what happens when tissues become chronically hypoxic.

Hypoxia as an Inflammation Driver

Injured, inflamed tissue is hypoxic by nature. Swelling compresses capillaries, reducing blood flow and oxygen delivery. This hypoxia activates HIF-1α (hypoxia-inducible factor-1 alpha), a transcription factor that upregulates pro-inflammatory genes, including those coding for TNF-α and IL-6. In other words: low oxygen = more inflammation = more low oxygen. The cycle sustains itself.

HBOT breaks this cycle by delivering oxygen at supraphysiologic concentrations — typically 1.5 to 2.0 atmospheres absolute (ATA), which dissolves oxygen directly in plasma at up to 10–20 times normal concentrations. This doesn't just oxygenate the tissue; it suppresses HIF-1α activity and the downstream inflammatory signaling it drives.

NF-κB Inhibition

The molecular mechanism with the most research support involves NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), the "master switch" of inflammation. NF-κB activation triggers transcription of TNF-α, IL-1β, IL-6, and dozens of other pro-inflammatory mediators.

Multiple studies have shown that HBOT downregulates NF-κB signaling. A 2019 study in International Immunopharmacology found that HBOT reduced NF-κB activation in inflammatory tissue models by 38–42%, with corresponding reductions in downstream cytokine production. This is the same target as corticosteroids and many biologic drugs — but through a different mechanism that doesn't carry their long-term risks.

Cytokine Suppression: The Data

Central Sensitization and Neuroplasticity

Beyond peripheral inflammation, chronic pain involves central sensitization — the spinal cord and brain amplify pain signals even when the original injury has healed. HBOT appears to address this through two mechanisms: reducing neuroinflammation in the CNS (evidence from traumatic brain injury research) and promoting neuroplasticity that can effectively "reset" sensitized pain pathways.

A landmark 2015 study by Efrati et al. in PLOS ONE used fMRI to map brain activity in fibromyalgia patients before and after HBOT. After 40 sessions, patients showed normalized activity in the insular cortex and prefrontal regions — the same areas that were hyperactivated before treatment. This was the first direct imaging evidence that HBOT modifies central sensitization, not just peripheral inflammation.

3. Fibromyalgia: The Strongest Clinical Evidence

Fibromyalgia presents an almost paradoxical challenge for conventional medicine: patients have measurable changes in neurological processing and inflammatory markers, yet standard imaging shows no tissue damage. This has led many physicians to dismiss the condition — and left patients cycling through treatments with limited effect.

It's also why the fibromyalgia evidence for HBOT is so significant. Efrati et al. conducted a randomized controlled trial (2015, PLOS ONE) with 60 female fibromyalgia patients who had failed standard treatment for at least two years. The HBOT group received 40 sessions at 2.0 ATA for 90 minutes each. Results:

• Pain scores (FIQ): Reduced by 38.4% in the HBOT group vs. 0.8% in control
• Tender point count: Decreased by 44% (control: no change)
• Sleep quality: Significantly improved in HBOT group
• Quality of life: 33% improvement on FIQ total score
• Brain activity: fMRI showed normalized pain-processing regions

Critically, the improvements in brain activity persisted at follow-up, suggesting HBOT produced lasting neuroplastic changes rather than temporary symptom suppression.

A 2022 follow-up study examined whether the neurological improvements persisted. Patients who completed the full 40-session protocol maintained significant pain reduction at 3-month follow-up, with some patients choosing maintenance sessions (2–3 per week) to sustain benefits.

4. Rheumatoid Arthritis, CRPS, and Surgical Recovery

Rheumatoid Arthritis (RA)

Rheumatoid arthritis is a systemic autoimmune condition where TNF-α and IL-6 are the primary drivers of joint destruction. The success of biologic drugs that target these exact cytokines (adalimumab, tocilizumab) validates them as therapeutic targets — and HBOT addresses both.

The evidence in RA is still emerging, largely from animal models and small human studies. What's been demonstrated:

• In murine collagen-induced arthritis (CIA) models, HBOT reduced joint inflammation scores by 30–40%, with measurable drops in TNF-α and IL-1β
• A pilot study of 20 RA patients showed reduced morning stiffness and joint swelling after 20 HBOT sessions, with CRP (C-reactive protein) reduction of 22%
• HBOT appears to enhance the efficacy of methotrexate when used concurrently, based on a small open-label study

Important caveat: RA is not a primary HBOT indication, and patients on biologics or DMARDs should consult their rheumatologist before adding HBOT. The immunomodulatory effects could theoretically interact with existing immunosuppressive therapy.

Complex Regional Pain Syndrome (CRPS)

CRPS — characterized by disproportionate, burning pain following an injury or surgery — involves a combination of neuroinflammation, sympathetic nervous system dysfunction, and central sensitization. It's one of the most debilitating pain conditions and notoriously treatment-resistant.

HBOT's multi-modal mechanism makes it particularly relevant for CRPS. A 2018 case series by Efrati et al. treated 13 CRPS patients with 60 HBOT sessions (2.0 ATA, 90 minutes). All 13 patients showed measurable improvement; 9 of 13 achieved remission or near-remission at the study endpoint. Pain scores dropped an average of 67%.

While case series have inherent limitations, the magnitude of response in a treatment-resistant population is notable. Several pain clinics in Europe now offer HBOT as an adjunct for CRPS management.

Post-Surgical Pain

Post-operative pain — particularly after orthopedic surgery, abdominal procedures, and joint replacements — is increasingly recognized as a risk factor for chronic pain development. The inflammatory cascade triggered by surgery can, in susceptible patients, transition from acute to chronic.

HBOT's role in wound healing and tissue repair (its most established clinical application) directly addresses post-surgical inflammation. Studies in post-surgical pain show:

• Faster reduction in CRP and other inflammatory markers vs. standard care alone
• Reduced need for opioid analgesics in the post-operative period
• Accelerated surgical site healing, particularly in cases with compromised perfusion
• Lower rates of chronic post-surgical pain at 6-month follow-up in some cohorts

For patients planning elective surgery, pre-treatment with HBOT (10–20 sessions before the procedure) is being studied as a way to optimize tissue oxygenation and reduce inflammatory load before the surgical insult occurs.

5. Home Chamber Protocols for Pain Management

Clinical HBOT trials typically use hard-shell chambers at 2.0–2.4 ATA with 100% oxygen. Home chambers operate at 1.3–1.5 ATA with ambient or supplemental oxygen. This is a meaningful difference — but not a disqualifying one for pain management.

Milder hyperbaric exposures still suppress NF-κB, reduce circulating cytokines, and promote tissue oxygenation. The effect size is smaller, but for maintenance and ongoing management (rather than acute clinical intervention), the lower-pressure home protocol can still deliver meaningful benefit.

Recommended Home Protocol for Chronic Pain

Most home chamber users targeting pain report initial benefit at 15–25 sessions, with significant improvement by session 40. The full loading phase (40–60 sessions) is important — several clinical studies found that incomplete treatment (fewer than 30 sessions) produced much weaker results.

Oxygen Supplementation

For pain management specifically, adding an oxygen concentrator to your home chamber setup meaningfully increases the therapeutic effect. At 1.3 ATA with ambient air, the oxygen partial pressure is approximately 1.3 × 0.21 = 0.27 ATA. With a concentrator delivering 90–95% oxygen, this jumps to ~1.3 × 0.93 = 1.21 ATA pO₂ — closer to the clinical protocol. This matters for driving cytokine suppression through the NF-κB pathway.

Stacking with Anti-Inflammatory Lifestyle Factors

HBOT works best as part of a comprehensive inflammation management approach, not as a standalone intervention. Evidence-supported stacks for chronic pain:

• Cold therapy: Cold plunge or contrast shower within 2 hours of HBOT extends the anti-inflammatory window. Cold activates norepinephrine release which independently reduces TNF-α.
• Omega-3 supplementation: EPA/DHA provides substrate for anti-inflammatory eicosanoid production. 3–4g/day is the dose used in most clinical trials with measurable effect on CRP.
• Sleep optimization: IL-6 and TNF-α are significantly elevated by sleep deprivation (even partial). HBOT's anti-inflammatory effect is substantially undermined by inadequate sleep.
• Low-glycemic diet: Postprandial glucose spikes transiently activate NF-κB — the same pathway HBOT suppresses. A high-glycemic diet blunts HBOT's cytokine-lowering effect.

6. Condition-Specific Considerations

Fibromyalgia Patients

Fibromyalgia patients respond most strongly to the full 40-session clinical protocol. The neuroplastic changes documented in the Efrati RCT appear to require sustained exposure to be durable. Key points:

• Expect a latency period — many fibromyalgia patients don't feel significant benefit until sessions 15–20
• Sleep improvement often precedes pain reduction as a first signal that the protocol is working
• Cognitive fog ("fibro fog") improvements have been reported, likely due to reduced neuroinflammation
• Maintenance sessions are important — without 2–3 weekly sessions, benefits fade within 2–3 months in many patients

Rheumatoid Arthritis Patients

• Always coordinate with your rheumatologist — do not discontinue DMARDs or biologics without medical supervision
• HBOT appears most useful as adjunct therapy during RA flares and for managing residual joint pain
• Avoid HBOT during active severe flares with joint temperature elevation (hyperthermia in an oxygen-enriched environment warrants caution)
• CRP monitoring is useful to track anti-inflammatory response objectively

CRPS Patients

• CRPS appears to respond to higher total session counts (40–60) rather than the standard 40-session protocols used in other conditions
• Clinical chamber access (2.0 ATA) produces dramatically better outcomes than home chambers for established CRPS — home chamber use may be better suited to maintenance after clinical treatment
• The 2018 Efrati case series used 60 sessions; pursuing fewer than 40 sessions is unlikely to produce durable benefit in CRPS

Post-Surgical Pain Patients

• Start HBOT as early as your physician permits post-operatively — the anti-inflammatory window matters most in the first 2–4 weeks
• Home chambers are well-suited to post-surgical use given the mobility limitations of the recovery period
• Daily sessions (rather than 5 days/week) produce faster inflammatory resolution in the immediate post-surgical phase

7. Safety Considerations for Pain Patients

HBOT has a well-established safety record, but chronic pain patients often have comorbidities and polypharmacy that require additional consideration. See our complete HBOT safety and side effects guide for the full picture.

Contraindications Relevant to Pain Patients

Common Side Effects in Pain Patients

The most common side effects are mild and transient: ear pressure (similar to air travel), mild fatigue in the first week, and occasional lightheadedness. Oxygen toxicity is not a practical concern at home chamber pressures (1.3–1.5 ATA with ambient or concentrator oxygen) — it becomes relevant at clinical pressures above 2.0 ATA in continuous, long-duration protocols.

Some fibromyalgia patients report a temporary increase in pain sensitivity during the first 5–10 sessions — a phenomenon consistent with the initial neuroplastic remodeling phase. This typically resolves by session 15 and is followed by sustained improvement.

8. Home Chamber vs. Clinical HBOT for Pain: Making the Right Choice

The decision between home and clinical HBOT for chronic pain is more nuanced than for other indications. Here's how to think about it:

For most chronic pain patients, the practical recommendation is: complete an initial clinical HBOT course (20–40 sessions) if you can access and afford it, particularly for fibromyalgia and CRPS where higher pressure has stronger evidence. Then use a home chamber for maintenance (2–4 sessions per week ongoing).

If clinical access is not practical, a home chamber protocol with an oxygen concentrator at 1.3–1.5 ATA, 90 minutes per session, 5–7 days per week for 8–12 weeks is still a reasonable evidence-informed approach — particularly for RA management and post-surgical recovery.

To understand the full cost picture of home vs. clinical sessions, see our hyperbaric chamber cost guide.

Frequently Asked Questions

Can hyperbaric oxygen therapy help with chronic pain?

Research suggests it can, particularly for conditions with a strong inflammatory and neurological component like fibromyalgia and CRPS. A 2015 RCT showed 38% pain score reduction in treatment-resistant fibromyalgia. Evidence for other chronic pain conditions is emerging. The mechanism — cytokine suppression via NF-κB inhibition and central sensitization modulation — is well-characterized. Results vary significantly by condition, pressure used, and total session count.

How does HBOT reduce inflammation at the molecular level?

HBOT delivers oxygen at supraphysiologic concentrations that suppress NF-κB, the master transcription factor controlling inflammatory gene expression. This reduces production of TNF-α, IL-6, and IL-1β — the primary cytokines driving chronic pain and tissue inflammation. HBOT also suppresses HIF-1α (the hypoxia-driven amplifier of inflammation) and elevates anti-inflammatory mediators like IL-10.

How many HBOT sessions are needed for chronic pain management?

Clinical research protocols typically use 40 sessions at 90 minutes each, 5 days per week. Home chamber users often require more total sessions (50–60) to achieve equivalent benefit due to lower operating pressure. Initial benefit typically appears at 15–25 sessions; full protocol benefit requires completing 40–60 sessions. Maintenance at 2–4 sessions per week is recommended to sustain results.

Is HBOT FDA-approved for fibromyalgia or arthritis?

No. HBOT has 13 FDA-approved indications, primarily wound healing, decompression sickness, and radiation injury. Fibromyalgia, rheumatoid arthritis, and CRPS use is off-label. Off-label use is legal and common — many effective medical interventions are used off-label — but it means insurance coverage is less likely and the physician oversight requirement is more important, not less.